BioCorRx (OTC:BICX) has begun a controversial pilot program to provide soon-to-be-released Louisiana prison inmates an opioid addiction treatment implant that has not been approved by the FDA. The pilot, announced last week, has drawn praise from corrections officials and concern from prisoner advocates and some medical professionals, according to a report in The Advocate, a Baton Rouge, La. newspaper. Ten […]
BioCorRx wins $5.6m grant for sustained release naltrexone implant
BioCorRx (OTC:BICX) announced this month that it won a two-year grant from the NIH’s National Institute on Drug Abuse to support the development of its sustained release naltrexone implant for the treatment of opioid use disorder. The grant includes $2.8 million for Feb. 1, 2019 to Jan. 31, 2020, followed by $2.8 million for the second […]
Anthem exec chairman joins Proteus board | Personnel Moves – Feb. 26, 2018
Proteus Digital Health announced earlier this month that Anthem‘s (NYSE:ANTM) executive chairman, Joseph Swedish, joined the company’s board of directors. Swedish served as Anthem’s president & chief executive from 2013 until he was appointed executive chairman in 2018. Get the full story at our sister site, Drug Delivery Business News.
BioCorRx inks deal with Nat’l Institute on Drug Abuse
BioCorRx (OTC:BICX) said today that it inked a confidentiality agreement with the National Institute on Drug Abuse, which will allow the group to share information and potentially work together on R&D and commercialization of BioCorRx’s therapies for opioid use disorder. The National Institutes of Health division has also agreed to participate as an observer at the […]
BioCorRx partners with virtual reality center for naltrexone implant study
BioCorRx (OTC:BICX) said today that it partnered with the Virtual Reality Medical Center to conduct a study on the company’s long-lasting naltrexone implant. BioCorRx’s recovery program consists of a long-lasting implant that delivers an opioid antagonist, naltrexone, which reduces physical cravings for alcohol and opioids. The recovery service also has a counseling program specifically designed […]
BioCorRx to meet with the FDA for injectable, sustained-release opioid addiction therapy
BioCorRx (OTC:BICX) said today that the FDA has granted the anti-addiction developer a pre-investigational new drug meeting, scheduled for Sept. 19. The Anaheim, Calif.-based company said it is slated to review the development and marketing plan for BICX101, an injectable, sustained-release formulation of naltrexone as a therapy for opioid addiction and alcohol use disorders. Get […]
BioCorRx launches R&D program for anti-addiction naltrexone drug-device combo
Anti-addiction developer BioCorRx said today it launched a research & development initiative as it seeks FDA approval for its naltrexone implant designed to treat opioid and alcohol addictions. If you have problem with addictions then read this blog. The implant slowly releases naltrexone, a non-addictive opioid antagonist that can reduce physical cravings and block some […]
MassDevice Network
@MassDevice
LinkedIn
YouTube